Higher Mortality, MI and ESRD Risks for Tophaceous Gout Than Nontophaceous
Research finds risks for mortality, acute myocardial infarction, and end-stage renal disease in patients with gout are higher in tophaceous than nontophaceous.
Read More
Author: Teresa Sellinger
Adding a Kinase to Pembrolizumab May Increase CLL Treatment Efficacy
Adding BCR kinase inhibitor ibrutinib or idelalisib to monoclonal antibody pembrolizumab increases treatment efficacy in CLL with Richter transformation.
Read More
Efficacy and Safety of Nipocalimab in Sjögren’s Disease: Phase 2 Trial Results
Nipocalimab showed a significant decrease in Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.
Read More
Early Treatment With Ambrisentan Prevents PAH Development in Patients With SSc
In SSc plus mild pulmonary vascular disease, early treatment with ambrisentan effectively prevented pulmonary vascular disease progress and development of PAH.
Read More
Upadacitinib Show Promise for Treatment of Giant Cell Arteritis
Upadacitinib 15 mg demonstrated convincing results as a treatment for giant cell arteritis in the phase 3 SELECT-GCA trial.
Read More
Real-World Comparative Effectiveness of Advanced Therapies in Psoriatic Arthritis
PRO-SPIRIT study examines the real-world efficacy results of disease-modifying antirheumatic drugs for patients with psoriatic arthritis.
Read More
Key Predictors of Rheumatoid Arthritis Flares Identified
Baseline methotrexate use has been found to be able to predict remission flare ups in patients with rheumatoid arthritis.
Read More
Anti-Ro/SSA Antibodies in Systemic Sclerosis: a Novel Predictor of Severe Lung Involvement
Research suggests including anti-SSA antibodies in routine clinical practice could notably improve the risk stratification of patients with SSc
Read More
Dual IL-17 Blocker Significantly Reduces Spinal Radiographic Progression in R-axSpA
Bimekizumab has been found to minimize spinal radiographic progression in patients with radiographic axial spondyloarthritis.
Read More
Molecular Testing Appears To Be Increasing in eNSCLC
An increasing number of patients with eNSCLC currently have access to biomarker testing and targeted therapies, according to the MYLUNG consortium.
Read More
Spotlight On the 42nd ASRS Annual Scientific Meeting July 17-20
Immerse yourself in retinal science advancements, therapeutics, innovation and fellowship at the 42nd ASRS Annual Scientific Meeting July 17-20, 2024.
Read More
Achilles Tendon Involvement in PsA Linked to Persistent Pain and Severe Functional Impairment
Structural and functional differences in the Achilles tendon could be clinically relevant when managing pain in patients with psoriatic arthritis.
Read More
Zanubrutinib Plus Venetoclax Shows Promise in Del(17p)/TP53-Mutated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Zanubrutinib plus venetoclax delivered promising preliminary efficacy results in newly diagnosed CLL/SLL in participants with del(17p) and/or TP53 mutations.
Read More
Mosunetuzumab Benefits Outcomes Across Follicular Lymphoma Subgroups
Patients with pre-treated relapsed or refractory follicular lymphoma have shown benefits with mosunetuzumab.
Read More
Promising Results for Anitocabtagene Autoleucel Therapy in Multiple Myeloma
Anitocabtagene autoleucel therapy showed promising results in patients with relapsed or refractory multiple myeloma.
Read More
Revumenib Displays Encouraging Anti-Tumor Activity in KMT2Ar Acute Leukemia, AUGMENT-101 Trial Stopped Early
The AUGMENT-101 trial in patients with in KMT2Ar leukemia has been stopped early because of revumenib encouraging anti-tumor activity.
Read More
Is Pelabresib + Ruxolitinib the Paradigm-Shifting Combo Therapy for Myelofibrosis?
Pelabresib plus ruxolitinib has shown efficacy in the treatment responses of patients with myelofibrosis.
Read More
Sovleplenib Delivers Durable Responses and QOL Improvements in Primary Immune Thrombocytopenia
Sovleplenib may offer QOL improvements for patients with primary immune thrombocytopenia.
Read More
Multiple Novel Oral Agents Show Promise in Psoriasis
Oral agents have show good efficacy results in patients with psoriasis. An oral agent is also easier for patients to intake then other forms of medication.
Read More
The Unfavorable Role of Obesity in Psoriatic Disease
The association between obesity and psoriatic disease. Smoking, genetics, as well as obesity, all potentially contribute to the development of psoriasis in all age groups.
Read More